ZYUS Life Sciences Corporation (TSXV:ZYUS)
Canada · Delayed Price · Currency is CAD 0.7100
+0.0400 (5.97%)
Aug 12, 2025, 4:00 PM EDT
ZYUS Life Sciences Company Description
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union.
The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer.
ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.
ZYUS Life Sciences Corporation
| Country | Canada |
| Founded | 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Brent Zettl |
Contact Details
Address: Unit 204 Saskatoon, Ontario S7N 4L8 Canada | |
| Phone | 888 651 9987 |
| Website | zyus.com |
Stock Details
| Ticker Symbol | ZYUS |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Brent H. Zettl | President, Chief Executive Officer, Secretary and Director |
| John M. Hyshka | Chief Financial Officer |
| Keith Carpenter CFA | Chief Strategy and Investment Officer |
| Michelle Gursky | Vice President of Legal Affairs |
| Scott William Livingstone | Vice President of Clinical Research |
| Tim Miller | Director of Investor Relations and Capital Markets |
| Dr. Julie Stakiw FRCPC, M.D. | Chief Medical Officer |